Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Dec;8(23):1616.
doi: 10.21037/atm-20-4268.

Transarterial chemoembolization (TACE) plus sorafenib: a real winning combination?

Xavier Adhoute  1 , Rodolphe Anty  2 , Marc Bourlière  1
Affiliations
Editorial

Transarterial chemoembolization (TACE) plus sorafenib: a real winning combination?

Xavier Adhoute et al. Ann Transl Med. 2020 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure from (available at http://dx.doi.org/10.21037/atm-20-4268). XA reports other from Bayer, other from Ipsen, other from Eisai, outside the submitted work. RA reports other from Gliead, other from Bayer, other from Eisai, other from Intercept, other from Abbvie, other from MSD, other from Ipsen, outside the submitted work. MB reports other from Merck-Schering Plough, other from Gliead, other from Janssen, other from Vertex, other from Boehringer-Ingelheim, other from BMS, other from Roche, other from Abbvie, other from GSK, outside the submitted work.

Figures

Figure 1
Figure 1
“unTACEable Progression” concept: an emerging consensus (5,18-24). ART, Assessment for Retreatment with Transarterial Chemoembolization; EASL, European Association for the Study of the Liver; TACE, transarterial chemoembolization; EHS, extra hepatic spread; MVI, macro vascular invasion; CP, Child-Pugh; PS, performance status; mRECIST, modified Response Evaluation Criteria in Solid Tumors; RECICL, Response Evaluation Criteria in Cancer of the Liver.
See this image and copyright information in PMC

Comment on

References

    1. Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011;55:1309-16. 10.1016/j.jhep.2011.03.007 - DOI - PubMed
    1. Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014;111:255-64. 10.1038/bjc.2014.199 - DOI - PMC - PubMed
    1. Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011;37:212-20. 10.1016/j.ctrv.2010.07.006 - DOI - PubMed
    1. Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology 2016;64:106-16. 10.1002/hep.28453 - DOI - PubMed
    1. Labeur TA, Takkenberg RB, Klumpen HJ, et al. Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2019;42:230-8. 10.1007/s00270-018-2118-6 - DOI - PMC - PubMed